DAILYZ HEALTH NEWS

A global analysis of 10,000 knee arthritis patients found knee braces, water therapy, and exercise outperform drug treatments in pain relief and function.

Health

March 30, 2026 Evan Vega

FDA Greenlights Avlayah (tividenofusp alfa-eknm) for Hunter Syndrome in Specific Patients on March 24

The FDA approved Avlayah (tividenofusp alfa-eknm) for treating neurologic Hunter syndrome in pediatric patients weighing at least 5 kg.

Health

March 30, 2026 Evan Vega

FDA Approves Lifyorli (relacorilant) for Platinum-Resistant Ovarian Cancer on March 25

The FDA approved relacorilant (Lifyorli) with nab-paclitaxel for platinum-resistant ovarian cancer, based on improved progression-free survival in a phase 3 trial.

Health

March 29, 2026 Evan Vega

Sotyktu (deucravacitinib) Awaits FDA Decision by March 6 for Adults with Active Psoriatic Arthritis

The FDA approved Sotyktu (deucravacitinib) on March 6, 2026, for adults with active psoriatic arthritis based on positive phase 3 trial results.

Health

March 29, 2026 Evan Vega

FDA Approves Nivolumab Addition to AVD Chemotherapy for Patients 12 and Older with Hodgkin Lymphoma

The FDA approved nivolumab with AVD chemotherapy for patients 12+ with untreated Stage III/IV classical Hodgkin lymphoma.

Health

March 28, 2026 Evan Vega

FDA Greenlights Nivolumab Plus AVD Regimen for Untreated Classic Hodgkin Lymphoma in March

The FDA approved nivolumab plus AVD for untreated Stage III/IV classical Hodgkin lymphoma in patients aged 12 and older.

Health

March 28, 2026 Evan Vega

GSK Resubmits Tebipenem HBr NDA for Complicated UTIs After Phase 3 Non-Inferiority Data

GlaxoSmithKline resubmitted its NDA for tebipenem HBr to the FDA for complicated UTIs after positive Phase 3 non-inferiority trial results.

Health

March 26, 2026 Evan Vega

Gilead Submits NDA for Bulevirtide, First Potential HDV Treatment, Backed by Phase 3 MYR301 Data

Gilead Sciences submitted an NDA to the FDA for bulevirtide 10 mg to treat chronic hepatitis delta virus, supported by Phase 3 MYR301 data.

Health

March 26, 2026 Evan Vega

FDA Extends Review of Reproxalap for Dry Eye Disease to March 16 Amid Clinical Study Requests

The FDA extended its review of Aldeyra’s reproxalap for dry eye disease to March 16, 2026, after requesting a clinical study report.

Health

March 25, 2026 Evan Vega

FDA Approves Icotyde (icotrokinra) for Moderate-to-Severe Plaque Psoriasis in Patients 12 and Older

The FDA approved ICOTYDE (icotrokinra) for treating moderate-to-severe plaque psoriasis in patients 12 and older weighing at least 40 kg.

DAILYZ HEALTH NEWS

DAILYZ HEALTH NEWS

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

Doctors Without Borders Worker Evacuated After Contracting Ebola in Democratic Republic of Congo Outbreak

FDA issues emergency use authorization for drugs to prevent and treat New World screwworm in dogs and cats

FDA approves first drug to treat Alexander disease, offering a targeted therapy for the ultra-rare, progressive neurodegenerative disorder in children

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

Doctors Without Borders Worker Evacuated After Contracting Ebola in Democratic Republic of Congo Outbreak

FDA issues emergency use authorization for drugs to prevent and treat New World screwworm in dogs and cats

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

Doctors Without Borders Worker Evacuated After Contracting Ebola in Democratic Republic of Congo Outbreak

FDA issues emergency use authorization for drugs to prevent and treat New World screwworm in dogs and cats

FDA approves first drug to treat Alexander disease, offering a targeted therapy for the ultra-rare, progressive neurodegenerative disorder in children

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

Doctors Without Borders Worker Evacuated After Contracting Ebola in Democratic Republic of Congo Outbreak

FDA issues emergency use authorization for drugs to prevent and treat New World screwworm in dogs and cats

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

Doctors Without Borders Worker Evacuated After Contracting Ebola in Democratic Republic of Congo Outbreak

FDA issues emergency use authorization for drugs to prevent and treat New World screwworm in dogs and cats

FDA approves first drug to treat Alexander disease, offering a targeted therapy for the ultra-rare, progressive neurodegenerative disorder in children

Simple Therapies Outperform Drugs in Major Analysis of 10,000 Knee Arthritis Patients

FDA Greenlights Avlayah (tividenofusp alfa-eknm) for Hunter Syndrome in Specific Patients on March 24

FDA Approves Lifyorli (relacorilant) for Platinum-Resistant Ovarian Cancer on March 25

Sotyktu (deucravacitinib) Awaits FDA Decision by March 6 for Adults with Active Psoriatic Arthritis

FDA Approves Nivolumab Addition to AVD Chemotherapy for Patients 12 and Older with Hodgkin Lymphoma

FDA Greenlights Nivolumab Plus AVD Regimen for Untreated Classic Hodgkin Lymphoma in March

GSK Resubmits Tebipenem HBr NDA for Complicated UTIs After Phase 3 Non-Inferiority Data

Gilead Submits NDA for Bulevirtide, First Potential HDV Treatment, Backed by Phase 3 MYR301 Data

FDA Extends Review of Reproxalap for Dry Eye Disease to March 16 Amid Clinical Study Requests

FDA Approves Icotyde (icotrokinra) for Moderate-to-Severe Plaque Psoriasis in Patients 12 and Older